An investigational combination therapy from Eli Lilly led to significant weight loss in a mid-stage study, but high discontinuation rates raise questions about tolerability.
An investigational combination therapy from Eli Lilly led to significant weight loss in a mid-stage study, but high discontinuation rates raise questions about tolerability.
<iframe src="https://statesidedaily.com/embed/cluster/1271a9d8dbfa5f3ae615e94995f94b7c42004360" width="100%" height="320" style="border:0;max-width:680px" loading="lazy" title="STAT+: Eli Lilly’s Zepbound combined with amylin drug led to significant weight loss in mid-stage trial"></iframe>
